Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 13/20 | 0.46 |
| ▸ | AXL | P30530 | 12/20 | 0.46 |
| ▸ | CFD | P00746 | 3/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462368 | 0.90 | MERTK (0.43) | MERTKAXLPIK3C3MET | |
| SCHEMBL3460453 | 0.89 | MET (0.45) | MERTKAXLPIK3C3MET | |
| SCHEMBL3461403 | 0.87 | MERTK (0.43) | MERTKAXLPIK3C3MET | |
| SCHEMBL3461708 | 0.84 | PIK3CD (0.51) | — | |
| SCHEMBL3461941 | 0.84 | PIK3CD (0.51) | — | |
| SCHEMBL13401171 | 0.84 | PIK3CD (0.51) | — | |
| SCHEMBL3462510 | 0.84 | MERTK (0.43) | MERTKAXLPIK3C3MET | |
| SCHEMBL3461547 | 0.84 | AXL (0.42) | MERTKAXLPIK3C3MET | |
| SCHEMBL3460036 | 0.81 | PDE4A (0.37) | MERTKAXLCFDKDM4E | |
| SCHEMBL3461360 | 0.79 | ATR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | MERTK 833/4885AXL 895/4885CFD 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.